Evolutionary precision medicine: A role for repeat epidermal growth factor receptor analysis in ALK-rearranged lung adenocarcinoma?

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3681-3683

  Birkbak, Nicolai Juul ^a   Hiley, Crispin T ^a   Swanton, Charles ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CERITINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLONAL VARIATION; EDITORIAL; EVOLUTIONARY ALGORITHM; EVOLUTIONARY PRECISION MEDICINE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG RESECTION; MEDICINE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE SECTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; ADENOCARCINOMA; FEMALE; GENETICS; LUNG TUMOR; MALE; MUTATION; PATHOLOGY;

ADENOCARCINOMA; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84947466252     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.2976     Document Type: Editorial

References (25)

1. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-550, 2014
2. Choi YL, Takeuchi K, Soda M, et al: Identification of novel isoforms of the EML4-ALK transforming gene in non-small-cell lung cancer. Cancer Res 68:4971-4976, 2008
3. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007
4. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
5. Mano H: Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 99:2349-2355, 2008
6. Gainor JF, Varghese AM, Ou SH, et al: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: An analysis of 1, 683 patients with non-small-cell lung cancer. Clin Cancer Res 19:4273-4281, 2013
7. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
8. Doebele RC, Pilling AB, Aisner DL, et al: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer. Clin Cancer Res 18:1472-1482, 2012
9. Katayama R, Shaw AT, Khan TM, et al: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4:120ra17, 2012
10. Friboulet L, Li N, Katayama R, et al: The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small-cell lung cancer. Cancer Discov 4:662-673, 2014
11. Shaw AT, Kim DW, Mehra R, et al: Ceritinib in ALK-rearranged non-smallcell lung cancer. N Engl J Med 370:1189-1197, 2014
12. McGranahan N, Swanton C: Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27:15-26, 2015
13. de Bruin EC, McGranahan N, Mitter R, et al: Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346:251-256, 2014
14. Zhang J, Fujimoto J, Zhang J, et al: Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346:256-259, 2014
15. Murugaesu N, Wilson GA, Birkbak NJ, et al: Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov doi: 10.1158/2159-8290. CD-15-0412 [epub ahead of print on May 23, 2015]
16. Yates LR, Gerstung M, Knappskog S, et al: Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 21:751-759, 2015
17. Jamal-Hanjani M, Hackshaw A, Ngai Y, et al: Tracking genomic cancer evolution for precision medicine: The lung TRACERx study. PLoS Biol 12:e1001906, 2014
18. Cai W, Lin D, Wu C, et al: Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinoma. J Clin Oncol 33:3701-3709, 2015
19. Wallander ML, Geiersbach KB, Tripp SR, et al: Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small-cell lung carcinoma: Implications for optimal clinical testing. Arch Pathol Lab Med 136:796-803, 2012
20. Sholl LM, Weremowicz S, Gray SW, et al: Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 8:322-328, 2013
21. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26, 2011
22. McGranahan N, Favero F, de Bruin EC, et al: Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med 7:283ra54, 2015
23. Su KY, Chen HY, Li KC, et al: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30:433-440, 2012
24. Le Quesne J, Maurya M, Yancheva SG, et al: A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material. J Thorac Oncol 9:769-774, 2014
25. Gillies RJ, Verduzco D, Gatenby RA: Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 12:487-493, 2012